Iron is a key micronutrient essential for many biological events. While iron deficiency can lead to anemia, supplementation with oral iron often ends up with enteral iron overload, a critical gastrointestinal (GI) burden linked to the increased risk of dysbiosis, infections and often associated with colorectal cancer. Iron chelation therapy is clinically used to reduce pathological systemic iron overload by established low molecular weight iron chelators. As drawbacks, these drugs present low pharmacokinetic profiles and several toxicities, leading to relatively high rates of adverse effects. To overcome these issues, the prevention of iron accumulation in the GI tract by non-absorbable iron binding polymers could represent an alternative still underexploited approach. Here, we present the development of a series of insoluble polymeric Fe(III) chelators. These innovative compounds have been obtained by the conjugation of 3-hydroxypyridin-4-one Fe(III) chelating moiety with branched Polyethyleneimine (PEI) and Carboxymethyl cellulose (CMC). In vitro binding studies indicated that the Fe(III) chelating capacity depends on the nature of the polymer. In particular, PEI derivatives possess higher selectivity toward Fe(III) in simulated intestinal fluid preserving the integrity of intestinal enterocytes, representing thus promising compounds in the development of iron chelators.
Nonabsorbable Iron(III) binding polymers : Synthesis and evaluation of the chelating properties / C.A. Ghisalberti, E. Falletta, C. Lammi, G. Facchetti, R. Bucci, E. Erba, S. Pellegrino. - In: POLYMER TESTING. - ISSN 0142-9418. - 90:(2020 Oct), pp. 106693.1-106693.7. [10.1016/j.polymertesting.2020.106693]
Nonabsorbable Iron(III) binding polymers : Synthesis and evaluation of the chelating properties
E. Falletta;C. Lammi;G. Facchetti;R. Bucci;E. Erba;S. Pellegrino
2020
Abstract
Iron is a key micronutrient essential for many biological events. While iron deficiency can lead to anemia, supplementation with oral iron often ends up with enteral iron overload, a critical gastrointestinal (GI) burden linked to the increased risk of dysbiosis, infections and often associated with colorectal cancer. Iron chelation therapy is clinically used to reduce pathological systemic iron overload by established low molecular weight iron chelators. As drawbacks, these drugs present low pharmacokinetic profiles and several toxicities, leading to relatively high rates of adverse effects. To overcome these issues, the prevention of iron accumulation in the GI tract by non-absorbable iron binding polymers could represent an alternative still underexploited approach. Here, we present the development of a series of insoluble polymeric Fe(III) chelators. These innovative compounds have been obtained by the conjugation of 3-hydroxypyridin-4-one Fe(III) chelating moiety with branched Polyethyleneimine (PEI) and Carboxymethyl cellulose (CMC). In vitro binding studies indicated that the Fe(III) chelating capacity depends on the nature of the polymer. In particular, PEI derivatives possess higher selectivity toward Fe(III) in simulated intestinal fluid preserving the integrity of intestinal enterocytes, representing thus promising compounds in the development of iron chelators.File | Dimensione | Formato | |
---|---|---|---|
Draft.pdf
Open Access dal 16/10/2022
Tipologia:
Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione
669.8 kB
Formato
Adobe PDF
|
669.8 kB | Adobe PDF | Visualizza/Apri |
1-s2.0-S0142941820308631-main.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
1.01 MB
Formato
Adobe PDF
|
1.01 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.